The present invention refers to the use of granules comprising surface-reacted calcium carbonate and one or more binder(s) as excipient in a pharmaceutical, nutraceutical, agricultural, veterinary, cosmetic, home, food, packaging or personal care product, wherein the granules have i) a weight particle size d.sub.90 of 150 to 700 μm, as measured according to mechanical sieving, ii) a weight median particle size d.sub.50 of 45 to 300 μm, as measured according to mechanical sieving, iii) a weight particle size d.sub.10 of 18 to 100 μm, as measured according to mechanical sieving, and iv) a specific surface area of ≥15.0 m.sup.2/g as measured by the BET nitrogen method.

Disclosed are solid oral controlled-release pharmaceutical compositions of antibiotics/ antibacterials comprising a core consisting of a complex monolithic matrix comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac, and an outer coating of said core consisting of a layer comprising ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers. The compositions of the invention enable the frequency of administration to be reduced, and the release of the medicament in particular sites of the gastrointestinal tract to be controlled.

The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.

Disclosed is an oral sustained-release composition for an insoluble drug, which is especially suitable for a low-dose insoluble drug, the oral sustained-release composition comprises a sustained-release granule part and a gel skeleton part, the sustained-release granule part comprises the insoluble drug, an enteric material, and a strong liquid sorbent, and the gel skeleton part comprises a hydrophilic gel skeleton material; and the sustained-release granules are obtained by preparing the insoluble drug and the enteric material into a suspension and then spraying the suspension onto the strong liquid sorbent, the sustained-release granules are wrapped by the gel skeleton to form a multiple sustained-release system technology, which prolongs a release time, and has a simple preparation process, high efficiency, uniform drug mixing, and less content loss.

The present invention discloses 2-aminoindane Formulas I and II and their pharmaceutically acceptable salts, compositions and methods of use to modulate central nervous system activity, and to treat central nervous system disorders, such as post-traumatic stress, depression, anxiety, and adjustment disorders. In certain embodiments, the compounds of the present invention can be used for entactogenic therapy in counseling sessions, as needed periodically or consistently as necessary or desired.

Provided are methods and compositions for treating nocturnal symptoms of Parkinson's disease, morning akinesia, or associated symptoms thereof in a human subject in need thereof, wherein circulating plasma levels of levodopa are provided for an extended period of time following a period of delay after administration.

The present invention provides pharmaceutical compositions suitable for oral delivery of active agent, such as peptides and small molecules, and methods for treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance the bioavailability of therapeutic active agents.

The present invention relates to solid dispersions including, but not limited to, co-processed carbohydrates with different solubilities and concentrations, which have a microcrystalline plate structure. The solid dispersions, excipient systems and formulations of the present invention are highly compactable and durable and when compressed into solid dosage forms demonstrate uniform densification, low friability at low pressures, and and/or relatively constant low disintegration times at various hardnesses. The solid dosage forms of the present invention demonstrate superior organoleptics, disintegration, and/or robustness.

The invention provides a pharmaceutical composition comprising sodium lauryl sulfate, hydroxypropyl methylcellulose (HPMC), a copolymer of vinylpyrrolidone and vinyl acetate, and a therapeutically effective amount of metaxalone or a pharmaceutically acceptable salt thereof. Related processes and methods are also disclosed.

Provided are an orally disintegrating tablet that quickly disintegrates when it is placed in the mouth or put into water, provides favorable taste, has a sufficient hardness in general production, transportation and use and is excellent in terms of storage stability, and a process for the production of the same which is excellent in terms of industrial production. An orally disintegrating tablet containing a drug, a crystalline cellulose having a bulk density of 0.23 g/cm.sup.3 or less (preferably from 0.10 g/cm.sup.3 to 0.23 g/cm.sup.3), a sugar alcohol and a pregelatinized starch.